Joseph Knoll: Enhancer Sensitive Brain Regulations and Synthetic Enhancers (Selegiline, BPAP) which Counteract the Regressive Effects of Brain Aging

Chapter 9

Mechanisms of DEP's and BPAP's Anti-Aging Effect

Chapters 3 and 4 showed that the catecholaminergic and serotonergic neurons were identified and analyzed in detail as the first models of life-important enhancer-sensitive brain regulations.

Analyzing the molecular mechanism of BPAP's specific and non-specific enhancer effects, we clarified that the interaction with distinct sites on the VMAT2 is the main mechanism of action of the enhancer substances. This finding elucidates BPAP's highly characteristic bi-modal, bell-shaped concentration-effect curves (see Chapters 4 and 10).

Natural enhancers maintain biological vigor during the developmental-phase of life, from weaning until sexual maturity, on a hyperactive level (Knoll and Miklya 1995). Sexual hormones return the enhancer's activity back to its pre-weaning low level (Knoll, Miklya, Knoll and Dalló 2000) and due to post-developmental continuously progressing diminishment in the natural stimulation of the enhancer-sensitive brain regulations (Knoll 2012). Mammals' life is exactly limited to their TLS.

As summarized in detail in Chapter 6, we presented experimental evidence that as soon as sexual hormones terminate the developmental/uphill phase of life, the slow, continuous, progressively aging enhancer-sensitive brain-regulations begin and last until death. The amount of the natural enhancers show over time a downward tendency and the consequences are exactly measurable with the continuous, progressive decline of the appropriate brain functions.

We finally published in 2016 the first longevity study demonstrating that the enhancer effect of the DEP and BPAP are responsible for life extension. Using the enhancer-sensitive dopaminergic neuron as experimental model, we presented the first experimental evidence in a longevity study that since enhancer-sensitive neurons do not age (Knoll and Miklya 2016) *we can significantly extend the life expectancy of mammals by maintaining them during their post-developmental phase of life, on a low daily dose of a synthetic enhancer substance.*

DEP's pharmacological spectrum is unique (Chapter 3). It is worth to briefly recall that prior to the discovery of the enhancer-sensitive brain regulations the peculiar mode of DEP's effect on the nigrostriatal dopaminergic neurons appeared to represent a hitherto unknown brain regulation. A successful biochemical analysis supported this view.

We found in the early 1980s that the striata of rats treated with 0.25 mg/kg DEP daily for three weeks released five times more dopamine (DA) in the resting state and seven times more DA in response to KCl stimulation than the striata removed from rats treated daily with 0.1 ml/100 g saline. The striata were removed 24 hours after the last injection of saline or DEP, respectively. DEP increased the rate of utilization of DA in the striatum of DEP-treated rats. The increase in the turnover rate of DA in the striatum was due to the enhancement of the fractional rate constant of DA efflux and the significant increase in the DA content. We realized that the facilitation of striatal dopaminergic neurotransmission by long term treatment is highly specific. With regard to NE a significant decrease in the turnover rate and unchanged level of this amine in the brain stem was found (Zsilla and Knoll 1982) and no change in the turnover rate of serotonin (SE) treated daily with 0.25 mg/kg DEP for two weeks was detected (Zsilla, Szekely and Knoll 1986).

DEP, being the only PEA-derivative, free of the catecholaminergic property, made the discovery of the enhancer-sensitive regulation in the mammalian brain possible (Knoll 1998).

The discovery of the enhancer sensitive brain regulations and the development of DEP and BPAP, the synthetic enhancers, allowed a new approach to better understand the essence of brain aging and elaborate a previously unimaginable, simple and safe, method to prevent the manifestation of the regressive effect of brain aging. To characterize the essence of brain aging we analyzed the aging-related decline of two dopaminergic functions: sexual activity and learning ability.

The Age-related Decline of Sexual Activity

It is fascinating to compare the astonishing similarity in human and rat males in the age-related decline of the mesencephalic dopaminergic system and realize the same functional consequences, the progressing weakening and final extinction of the ejaculatory activity during their post-developmental phase of life.

Sexual activity in the human male is known to be influenced by a number of factors, such as good health, stable marriage, satisfactory sexual partner(s) and adequate financial and

social status. But even in the males who meet all the requirements for retention and maintenance of sexual functioning, there is an age-related decrease in sexual vigor.

In the Baltimore Longitudinal Study of Aging, coital activity was studied as function of age. They interviewed 628 members of the Washington-Baltimore area, varying from 20-95 years of age, white, married, urban residents in good health. According to this study the median coital activity was highest, **2.1** events/week, between ages of 30-34, and decreased progressively with increasing age, sinking to **0.2**/week in the age-group 65-69.

It is common knowledge that individual variation in sexual vigor is enormous. In this study, the mean frequency of total sexual activity in 159 males was found to be 520 sexual events/5 years in the age-group 20-39, including young males performing below 100 sexual events/5 years and those with frequencies of total sexual activity over 1000 sexual events/5 years. In the age-group 65-79, the mean frequency of total sexual activity decreased to 75 sexual events/5 years, but even in this group subjects producing 400-700 sexual events/5 years were registered (Martin 1977).

In a number of longitudinal studies performed on male rats we observed that the age-related decline of coital activity in male rats and the striking individual differences in sexual performance in different age cohorts are essentially the same as in human males (Knoll, Dalló and Yen 1989; Knoll 1988, 1989, 1990, 1993). Because of brain aging, even the most sexually high performing males may lose their potency to ejaculate if they live long enough. In our studies on male CFY rats, we followed the sexual performance of the animals once a week from sexual maturity until death. We measured three patterns: mounting, intromission, and ejaculation. We found that in response to brain aging even the best performing individuals lost their potency to ejaculate no later than the completion of their second year of age (Knoll 1993). The results of our first longevity study (Knoll 1988; 1993) clearly proved in retrospect that the age-related decline of the sexual performance of male rats signals the decay of the enhancer regulation in the dopaminergic neurons over time.

As shown in Chapter 6, in this series of experiments, we selected 132 aged, *2-year-old* male rats and measured in four consecutive, weekly mating tests their sexual performance: mounting, intromission and ejaculation. Due to aging, the ability to ejaculate ceased in 2-year-old CFY rats. We classified the rats according to their sexual performance in the testing period as non-copulators (no sign of sexual activity), mounting rats (displayed mounting only), and sluggish rats (displayed mounting and intromission). Of the 132 rats 46 were found to be non-copulators (Group 1), 42 displayed mounting only (Group 2), and 44 rats proved to

be sluggish (Group 3). After the selection period, we started to treat half of the rats with saline (1 ml/kg) and half with DEP (0.25 mg/kg) three times a week, until they died. We tested their sexual performance once a week. The dying out of the 66 saline-treated rats showed that lifespan was inversely proportional to their sexual performance. As sexual performance is directly proportional to the functional state of the enhancer regulation in the dopaminergic neurons, we assume that rats die when the age-related decline in mesencephalic enhancer regulation reached a critical threshold. With regard to sexual performance: Group 1 < Group 2 < Group 3, thus, rats belonging to Group 1 are the closest to exceeding the critical threshold resulting in natural death and die out first, rats in Group 2 live longer, and rats in Group 3 live the longest.

We compared during the post-developmental phase of life in male rats the individual variation in sexual performance of 3-6-month-old male rats with the performance of their 2-year-old peers. Whereas 52.49% of 3-6-month-old male rats displayed ejaculations during the four consecutive mating tests, only 5.80% of 12-18-month-old males ejaculated, and none of the 24-month-old males were endowed with this faculty any longer.

Moreover, the age-related change in the percentage of animals belonging to the 'non-copulator' group clearly proved that enhancer regulation in the dopaminergic neurons is in continuous decline during the post-developmental phase of life. Only 5.51% of the 3-6-month-old males were sexually inactive, but 19.56% of the 12-18-month-old rats and 34.84% of the 24-month-old rats belonged to this group.

Due to the striking similarities between human and rat males in the age-related decline of their sexual activity it is hard to deny that the decay of the dopaminergic machinery over time plays the key role on the final loss of the ability to ejaculate, from which there is no escape. We demonstrated with a series of experiments that the treatment of male rats with DEP significantly enhanced their sexual activity and with the preventive administration of a small dose of DEP the loss of the ability to ejaculate was substantially shifted in time (Knoll, Dalló and Yen 1989; Knoll 1988, 1989, 1990, 1993; Yen, Dallo and Knoll 1982).

In Table 9.1, a brief summary of the results of our first longevity study, shows that the anti-aging effect of DEP was decisive even in a series of experiments performed on two-year-old rats which had already lost their ability to ejaculate.

Table 9.1 Illustration of the antiaging effect of DEP treatment. Data taken from the first longevity study (Knoll et al. 1994)				
Classification of the groups according to sexual performance before treatment	**Number of animals**	**Total number of mountings (M), intromissions (I) and ejaculations (E) of the groups during treatment**		
		M	**I**	**E**
Saline-treated rats				
Non-copulators	23	37	0	0
Mounting rats	21	425	54	0
Sluggish rats	22	477	231	0
DEP-treated rats				
Non-copulators	23	997	544	190
Mounting rats	21	1129	662	172
Sluggish rats	22	1696	1257	481

A second example demonstrates on young male CFY rats the dopamine-dependency of sexual performance and the significant anti-aging effect of DEP-treatment. We selected 90 males possessing full-scale sexual activity. Half of the population was treated with saline (1 ml/kg), the other half with DEP (0.25 mg/kg), three times a week, from the 25th week of age. The rats' sexual performance was tested once a week. In this study, the loss in the ability to ejaculate was selected as the age-related end stage. Saline-treated rats reached this stage at an average of **112±9** weeks. In contrast, DEP-treated rats reached it at an average of **150±12** weeks (P<0.001) (Knoll 1989). As sexual performance is a dopaminergic function, it became obvious that the enhanced activity of the mesencephalic dopaminergic neurons was responsible for the significantly retarded loss of the ability to ejaculate in the DEP-treated group.

The Dopamine-dependent Age-related Decline of Learning Ability

In a modified version of the shuttle box we analyzed the acquisition of a CAR over 5 consecutive days. The technique, originally published by Bovet, Bovet-Nitti and Oliverio in 1966, was described in Chapter 6.

Due to aging of the dopaminergic neurons, saline-treated 3-month-old rats are significantly better learners than their saline-treated 1-year-old peers (Fig. 9.1). Since synthetic enhancers keep the dopaminergic neurons working on a higher activity level, rats treated with 0.1 mg/kg DEP (Fig. 9.2), or 0.0001 mg/kg BPAP (Fig. 9.3) showed no sign of aging-related decay in the learning ability.



Figure 9.1. *Experimental evidence that 3-month-old rats are significantly better learners than their 1-year-old peers (P<0.001). Significance in the performance between the groups was evaluated by multi-factor analysis of variance (ANOVA). Rats were trained in the shuttle box with 100 trials per day. Conditioned avoidance responses (CARs).*



Figure 9.2. *Experimental evidence shows that in rats treated with 0.1 mg/kg DEP there is no sign of aging-related decay in the learning ability. Rats were trained in the shuttle box with 100 trials per day. Significance in the performance between the groups was evaluated by multi-factor analysis of variance (ANOVA). There was no significant difference in the acquisition of conditioned avoidance responses (CARs) between the 3-month-old rats treated with saline and 1-year-old rats treated with DEP.*



Figure 9.3*. The anti-aging effect of 0.0001 mg/kg BPAP. 1-year-old rats were treated for 10 months subcutaneously, 3-times a week, with 0.0001 mg/kg BPAP. Their performance was compared to saline-treated rats. Rats were trained in the shuttle box with 100 trials per day. Significance in the performance between the groups was evaluated by multi-factor analysis of variance (ANOVA). BPAP treated rats performed significantly better than their saline-treated peers (P<0.05).*

The first longevity study with the low enhancer doses of DEP and BPAP, shown in Chapter 6 (Fig. 6.5, Fig. 6.6 and Fig. 6.7), presented experimental evidence that the synthetic enhancers' primary important therapeutic effect is their unique ability to counteract brain aging (Knoll and Miklya 2016).

This longevity study was the first demonstration that lifelong treatment with 0.0001 mg/kg BPAP, the peak dose with the specific enhancer effect, completely prevented aging of learning ability. We used the learning test as a highly sensitive model to measure the aging-related decay of the dopaminergic neurons. The BPAP-treated rats performed in the shuttle box like the saline-treated 3-month-old rats. This finding is an unprecedented, convincing proof that the enhancer-sensitive dopaminergic neurons do not age. Thus, the development of the first synthetic enhancer substances guides the way to prevent the regressive effects of brain aging.

References:

Bovet D, Bovet-Nitti F, Oliverio A. Effects of nicotine on avoidance conditioning of inbred strains of mice, Psychopharmacol. 1966; 10: 1-5.

Knoll J. The striatal dopamine dependency of lifespan in male rats. Longevity study with (-)deprenyl, Mech. Ageing Dev. 1988; 46: 237-262.

Knoll J. The pharmacology of selegiline ((-)deprenyl). New aspects. Acta Neurol Scand Suppl. 1989;126:83-91.

Knoll J. Nigrostriatal dopaminergic activity, deprenyl treatment, and longevity. Adv Neurol. 1990; 53:425-9.

Knoll J. The pharmacological basis of the beneficial effect of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases, J Neural Transm Suppl. 1993; 40:69-91.

Knoll J. (-)Deprenyl (selegiline) a catecholaminergic activity enhancer (CAE) substance acting in the brain, Pharmacology and Toxicology. 1998; 82: 57-66.

Knoll J. How Selegiline ((-)-Deprenyl) Slows Brain Aging, Bentham e-Books, 2012.

Knoll J, Dalló J, Yen TT. Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl, Life Sci. 1989; 45: 525-531.

Knoll J, Miklya I. Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity. Rationale for prophylactic (-)deprenyl (selegiline) medication, Life Sci. 1995; 56: 611-620.

Knoll J, Miklya I. Longevity study with low doses of selegiline/(-)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP), Life Sci. 2016; 167: 32-38.

Knoll J, Miklya I, Knoll B, Dalló J. Sexual hormones terminate in the rat the significantly enhanced catecholaminergic/serotoninergic tone in the brain characteristic to the post-weaning period, Life Sci. 2000; 67: 765-773.

Knoll J, Yen TT, Miklya I. Sexually low performing male rats dies earlier than their high performing peers and (-)deprenyl treatment eliminates this difference. Life Sci 1994; 54: 1047-1057.

Martin C. Sexual activity in the aging male. In: J. Money, H. Musaph (Eds), Handbook of sexology, Elsevier, Amsterdam. 1977; pp. 813-824.

Yen TT, Dalló J, Knoll J. The aphrodisiac effect of low doses of (-)deprenyl in male rats. Pol J Pharmacol Pharm. 1982 Nov-Dec;34(5-6):303-8.

Zsilla G, Knoll J. The action of (-)deprenyl on monoamine turnover rate in rat brain. Adv Biochem Psychopharmacol. 1982; 31:211-7.

Zsilla G, Szekely AM, Knoll J. Influence of neurotransmitter rate and receptor density by repeated low doses of (-)-deprenyl, In: G. Biggio, P.F. Spano, G. Toffano, G.L. Gessa

(editors). Modulation of Central and Peripheral Transmitter Function. Liviana Press Padiva. 1986; pp. 443-446.

May 23, 2019